RPHM NASDAQ
Reneo Pharmaceuticals, Inc.
1W: +9.6%
1M: +27.3%
3M: +23.8%
1Y: -75.2%
3Y: -74.8%
$18.20
Last traded 2024-10-04 — delisted
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
Dark Pool
Short Interest
Supply Chain
Smart Money Score
No convergence signal
Key Statistics
Market Cap$60.8M
52W Range1.68-82.9
Volume437,523
Avg Volume16,856
Beta0.22
Dividend—
Analyst Ratings
Company Info
CEOGregory J. Flesher
Employees8
SectorHealthcare
IndustryBiotechnology
IPO Date2021-04-08
Websitereneopharma.com
18575 Jamboree Road
Irvine, CA 92612
US
Irvine, CA 92612
US
619 733 3852
About Reneo Pharmaceuticals, Inc.
Reneo Pharmaceuticals, Inc. is a biopharmaceutical firm in its clinical development phase, dedicated to creating therapies for individuals suffering from uncommon inherited mitochondrial disorders. The company's lead candidate, REN001, functions as a selective peroxisome proliferator-activated receptor delta agonist. This compound is currently undergoing Phase IIb clinical trials for patients with primary mitochondrial myopathies. Additionally, REN001 is being assessed in Phase 1b clinical trials for those diagnosed with long-chain fatty acid oxidation disorders and glycogen storage disease type V. Founded in 2014, Reneo Pharmaceuticals' headquarters are located in San Diego, California.
Latest News
No recent news
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Leonard Braden Micha | P-Purchase | 68,746 | $1.50 | 2024-09-25 |
| Leonard Braden Micha | P-Purchase | 29,600 | $1.41 | 2024-09-24 |
| Leonard Braden Micha | P-Purchase | 806 | $1.40 | 2024-09-18 |
| Leonard Braden Micha | P-Purchase | 55,300 | $1.36 | 2024-09-17 |
| Leonard Braden Micha | P-Purchase | 172,747 | $1.37 | 2024-09-16 |